# Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).

> **NCT02173990** · PHASE2 · TERMINATED · sponsor: **Centre Oscar Lambret** · enrollment: 40 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Aflibercept-FOLFIRI

## Key facts

- **NCT ID:** NCT02173990
- **Lead sponsor:** Centre Oscar Lambret
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2018-11-02
- **Final completion:** 2019-10-22
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2021-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02173990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02173990, "Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02173990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*